CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500764-35-00

Acronym

IFG-01-2022

Enrollment

2000

Registered

2022-10-12

Start date

2022-10-13

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hormone receptor positive (HER2neg/HR+) breast cancer in the first line therapeutic setting, Patients with advanced HER2-negative

Brief summary

progression-free survival, overall survival

Detailed description

progression-free survival, overall survival, health related quality of life FACT-G/FACT-B, occurence of side effects

Interventions

DRUGFULVESTRANT

DRUGANASTROZOLE

DRUGRIBOCICLIB

DRUGLETROZOLE

DRUGEXEMESTANE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
progression-free survival, overall survival	—

Secondary

Measure	Time frame
progression-free survival, overall survival, health related quality of life FACT-G/FACT-B, occurence of side effects	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026